艾迪药业：ACC017片Ⅲ期临床试验首例受试者成功入组

Core Viewpoint - The company, Aidi Pharmaceutical, has announced the initiation of a Phase III clinical trial for its self-developed anti-HIV drug, ACC017 tablets, aimed at evaluating its efficacy and safety in treatment-naive adults with HIV-1 [2]. Group 1 - Aidi Pharmaceutical is conducting a multi-center, randomized, double-blind, double-dummy Phase III study [2]. - The first subject for the Phase III clinical trial was successfully enrolled on November 7, 2025 [2].